Explore semaglutide's patent status, how compounding may occur during FDA-declared shortages, and what patients should know about safety and regulation.
A patent grants a company exclusive rights to manufacture, market, and sell a drug for a specific time. For semaglutide:
This exclusivity protects the innovation but also limits access to generics in the short term.
Semaglutide’s base patent expires in 2026, but Novo Nordisk has filed numerous secondary patents on:
Certain secondary patents may extend protection through 2033 or beyond, which could delay the introduction of generic alternatives even after the primary patent expires."
Access to semaglutide-based treatments may be influenced by pricing, insurance coverage, and the availability of commercially manufactured products. Please note that this is estimated costs, and you should reach out to your insurance provider or licensed healthcare provider to determine your costs.
Eden is a platform that connects individuals with licensed healthcare providers who can evaluate their health needs to determine their eligibility for semaglutide.
Semaglutide is protected by a series of patents, some of which may extend into the 2030s, limiting the immediate availability of lower-cost generic alternatives. Branded products such as Ozempic® and Wegovy® are FDA-approved, meaning they have undergone rigorous testing for safety, efficacy, and manufacturing quality.
Eden helps individuals connect with licensed healthcare providers who can determine whether or not you are an eligible candidate for GLP-1.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Yes. The primary patent for semaglutide expires in 2026. However, additional patents—covering formulations, delivery systems, and use cases—may extend exclusivity through 2033 or beyond, depending on regulatory and legal outcomes.
